Low levels of myostatin may impair muscular atrophy and dystrophy treatments

In a paper published in Nature Communications, researchers from University College London and colleagues showed that the myostatin (MSTN; GDF8) pathway is downregulated in muscle wasting or atrophying diseases, providing a potential explanation for why

Read the full 355 word article

User Sign In